$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
The principle (A) and an overview of the method (B) are depicted in Figure 1.
1. Preparation of the Buffer
- Prepare Binding/Wash buffer by dissolving sodium dihydrogen phosphate (50 mM) and sodium chloride (300 mM) in water and adjust the pH to 8.0. Additionally add Tween 20 (0.01% (m/v) final concentration), methionine (2% (m/v) final concentration) and albumin (0.1% (m/v) final concentration) and adjust to the required volume.
2. Preparation of the Magnetic Beads
Prepare the magnetic beads according to the instruction manual. Briefly:
- Resuspend the magnetic beads using a vortex.
- Transfer, for each sample, 10 μl of the resuspended magnetic beads (40 mg/ml) into a tube.
- Collect the magnetic beads using a magnet, until the supernatant is clear (+/- 30 sec) and remove the supernatant carefully.
- Wash the magnetic beads two times: resuspend the beads in 150 μl of Binding/Wash buffer. Migrate the magnetic beads to one side of the tube using a magnet until the supernatant is clear and carefully remove the supernatant.
- Use 40 μl of Binding/Wash buffer, for each sample, to resuspend the beads (10 mg/ml).
3. Affinity Capture Assay
Note: To measure the (cosmic) background radioactivity (0% radioactivity), no radiolabeled virus is added to a control sample 1. Instead, the same volume Binding/Wash buffer is added.
Note: 100% radioactivity is defined by a control sample 2 to which all components are added except the nanobody. Instead, the same volume Binding/Wash buffer is added.
- Bring 2000 cpm of 35S labeled (β-radiation) poliovirus Sabin strain type 19, diluted with Binding/Wash buffer to 80 μl into a 96-well microtiter plate.
- Add 10 μl of nanobody dilution to the wells.
- Mix for about 10 seconds using a shaker.
- Allow the samples to incubate for 1 hour at room temperature.
- Add 40 μl of the washed magnetic beads suspension and incubate for 10 minutes at room temperature, under continuously shaking.
- Separate the beads and the supernatant using a magnet and transfer the cleared supernatant into a tube.
4. Measurement of the Radioactivity
- Transfer 50 μl of the supernatant from step 3.6 into a counting flask.
- Add 3 ml of scintillation fluid and mix. Measure the radioactivity in a β-scintillation counter.
5. Recycling the Beads
- Collect the used magnetic beads in a tube and centrifuge at 500 x g for 2 minutes or until a clear supernatant is obtained.
- Remove the supernatant and resuspend the beads in 6 ml 0.5 M NaOH.
- Transfer the suspension to multiple tubes and incubate in an ultrasonic bath for 5 minutes.
- Use the magnets to collect the magnetic beads and remove the supernatant.
- Add 1 ml 2% SDS-solution to each tube and resuspend using a vortex. Boil during 5 minutes.
- Collect the beads and remove the supernatant. Resuspend the beads in 1 ml 0.2 M EDTA (pH=7).
- Incubate the tubes in an ultrasonic bath for 5 minutes and once more, remove the supernatant.
- Add 1 ml of water to each tube and resuspend the beads. Collect the beads and remove the supernatant. Repeat this wash step twice.
- Remove the supernatant and resuspend the beads in 1 ml 10 mM CoCl2 solution. Put on a shaker for 10 minutes.
- Remove the supernatant using a magnet to collect the beads and resuspend in 1 ml of Binding/Wash buffer.
- Remove the supernatant and wash the beads two times using 1 ml of 20% (v/v) ethanol
- Resuspend the beads in their original volume of 20% (v/v) ethanol to obtain regenerated beads in a concentration of 40 mg/ml.
6. Interpretation of the Results
- Control sample 1, in which no radiolabeled virus was added, will be used to correct for the background radioactivity and to set the 0% radioactivity value. Control sample 2, which does not contain nanobody and where consequently all radiolabeled virus remains in the supernatant, is set as the 100% radioactivity value.
- The percentage of radioactivity in the supernatant (= a %) is a measure of the overall precipitation (= 100 - a %) of the radiolabeled virus by the nanobody.
7. Representative Results
Representative results for this affinity capture assay are shown in Figures 2, 3 and 4. In Figure 2, the affinity of PVSS38C, a nanobody specific for poliovirus, is shown. The affinity of PVSS38C was tested for three different antigens of poliovirus: Native-antigen (N-antigen), Heated-antigen (H-antigen) and 14S subunits. N-antigen is the intact virus that is infectious. When the virus is heated (20 minutes at 56 °C) or attached to a solid surface (unpublished results), the conformation of the capsid changes, resulting in a (partial) loss of the viral RNA and the capsid protein VP4, and empty capsids are formed which are then called H-antigens. 14S subunits are assembly intermediates. These antigens are recognized by different sets of antibodies after immunization10 and possess therefore different epitopes and antigenic sites. In the figure the percentage of radioactivity found in the supernatant is represented as a function of the concentration of nanobody. It can be seen that the radioactivity in the supernatant of the samples containing radiolabeled 14S subunits decreases with increasing concentrations of the nanobody PVSS38C. This can be translated as an increase in the amount of poliovirus 14S subunits connected to the nanobody PVSS38C and indirectly to the magnetic beads. The capturing titer (= the concentration of nanobody necessary to capture 50% of radiolabeled virus) can be graphically calculated as 0.099 nM. No affinity of PVSS38C for the N-antigenic and H-antigenic form of poliovirus is observed. From these data it is interpreted that PVSS38C is interacting with an epitope that is exclusively present on the 14S subunit and not on the two other antigenic forms of poliovirus.
To demonstrate that the loss of radioactivity from the supernatant is only due to the specific affinity of the nanobody towards its antigens, the same assay was performed with Nb1, a nanobody generated against the lrpB transcriptional regulator of Sulfolobus sulfataricus and known to have no interaction with any poliovirus antigen. The result of this assay is shown in Figure 3. All radiolabeled virus remains in the supernatants showing that there is no reactivity of Nb1 against the three antigenic forms of poliovirus.
Reproducibility of the results was tested by repeating the experiment for a total of eight times for one given nanobody (i.e., PVSP29F) at different days and by different persons. The results are shown in Figure 4. The mean value of percentage radioactivity in the supernatant was calculated for each nanobody concentration and is represented in correspondence with its standard deviation.

Figure 1. An overview of the principle (A) and the method (B) of the assay. A. His-tagged nanobodies that specifically recognize a certain poliovirus antigen will be able to interact with the cobalt-coated magnetic beads and will precipitate the radioactively labeled virus. B. His-tagged nanobodies are added to radioactively labeled poliovirus and incubated. Cobalt-coated magnetic beads are added and magnetic separation of the bound/unbound antigen is performed. The radioactivity of the supernatant is measured and the amount of captured antigen can be derived.

Figure 2. Magnetic beads affinity capture of different poliovirus antigens by nanobody PVSS38C. The percentage of radioactivity found in the supernatant is represented as a function of the concentration of PVSS38C. For 14S a concentration-response relationship can be found, showing the interaction of PVSS38C with an epitope exclusively present on 14S. No significant interaction with N- , nor H-antigen can be detected, although a negligible non-specific capturing at very high concentrations is noticed.

Figure 3. Magnetic beads affinity capture of different poliovirus antigens by nanobody Nb1. The percentage of radioactivity found in the supernatant is represented as a function of the concentration of Nb1. Nb1 is known to have no interaction with any poliovirus-antigen or -subunit. Since 100 % of the radioactivity is found in the supernatant, no virus was non-specifically bound to Nb1. The loss of radioactivity in figure 2 is therefore only due to the specific affinity of the nanobody towards its antigens.

Figure 4. Reproducibility of the assay. The mean value of percentage radioactivity in the supernatant is represented as a function of the concentration of nanobody. The experiment was repeated eight times at different days and by different persons. The standard deviation is represented as vertical bars.